In this work, we indeed show that introducing a next-generation beneficial microbe, A. soehngenii, into mice with diet-induced MASLD can alter the response to insulin and influence hepatic and intestinal gene expression. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.